FRAMINGHAM, MA, October 24, 2006-GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) announced today that Geoffrey Cox, Ph.D., GTC's Chairman and CEO, is scheduled to present at the following upcoming conferences:
Tuesday, October 31, 2006 at 1:30 p.m. ET during the C.E. Unterberg, Towbin Life Sciences Conference. The conference is being held at the New York Palace Hotel, New York, NY from October 30-31, 2006.
Monday, November 6, 2006 at 10:15 a.m. ET during the Rodman & Renshaw 8th Annual Healthcare Conference. The conference is being held at the New York Palace Hotel, New York, NY from November 6-8, 2006.
Wednesday, November 8, 2006 at 8:40 a.m. GMT during the Cowen and Company 7th Annual Global Health Care Conference. The conference is being held at The Landmark London Hotel, London, UK from November 7-8, 2006.
All presentations will be webcast live and can be accessed by logging onto www.gtc-bio.com. Replays can be accessed from this same website and will be available within 24 hours of each presentation.
GTC Biotherapeutics develops, produces, and commercializes therapeutic proteins through transgenic animal technology. GTC obtained the first approval of a transgenically derived product anywhere in the world in August 2006. ATrynŽ, GTC's recombinant form of human antithrombin, was approved by the European Commission for use in patients with a hereditary antithrombin deficiency undergoing surgical procedures. ATrynŽ is in phase III studies to support a filing in the United States requesting approval in the hereditary deficiency indication. GTC is also working with LEO Pharma A/S of Denmark to develop ATrynŽ as a potential treatment for disseminated intravascular coagulation (DIC) in conjunction with severe sepsis as well as launch ATrynŽ commercially in Europe. A phase II study in DIC is planned to commence at the end of 2006. In addition, GTC established a strategic collaboration with LFB Biotechnologies of France in October 2006 to jointly develop recombinant forms of human plasma proteins and monoclonal antibodies. Building on initial research performed by LFB, the first program of the collaboration will be to develop recombinant human factor VIIa as a potential treatment for hemophilia with inhibitors. GTC has also recently been granted a patent in the United States for the production of any therapeutic protein in the milk of any transgenic mammal. GTC's transgenic production platform is particularly well suited to enabling cost effective development of proteins that are difficult to express in traditional recombinant production systems as well as those that are required in large volumes. Additional information is available on the GTC web site, http://www.gtc-bio.com.
CONTACT:
GTC Biotherapeutics, Inc.
Thomas E. Newberry
Vice President, Corporate Communications
(508) 370-5374 Feinstein Kean Healthcare for GTC Biotherapeutics, Inc.
Francesca DeVellis
(617) 577-8110
Copyright 2006 GTC Biotherapeutics, All Rights Reserved